A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia

doi:10.1038/npp.2010.79

Paper

A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia

Published Jun 16, 2010 · H. Nasrallah, S. Gopal, C. Gassmann-Mayer

Neuropsychopharmacology

Q1 SJR score

151

Citations

5

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

RCT

Large Human Trial

Very Rigorous Journal

Highly Cited

Study Snapshot

Paliperidone palmitate, a long-acting injectable antipsychotic, shows potential in improving outcomes in adults with symptomatic schizophrenia.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia

Sign up to use Study Snapshot

References

Citations